Fig. 2
From: The mode of progressive disease affects the prognosis of patients with metastatic breast cancer
The frequency of new lesions (NL) in hormone therapy and chemotherapy. (a) The frequency of NL in the drugs used for hormone therapy. (b) The frequency of NL in the drugs used for chemotherapy and targeted drugs (bevacizumab, trastuzumab or trastuzumab combined with pertuzumab). nsAI, non-steroidal aromatase inhibitor; sAI, steroidal aromatase inhibitor; SERM, selective estrogen receptor modulator; SERD, selective estrogen receptor down-regulator; PTX + BV, paclitaxel with bevacizumab